Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Relay Therapeutics to “Sell” from “Hold,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $25.83.
• Relay Therapeutics reported a quarterly loss of $0.41 per share, missing estimates by $0.02, while revenue of $350,000 fell short of the $960,000 consensus forecast.
• Insiders sold 409,639 shares worth approximately $7.23 million over the past 90 days, while institutional investors and hedge funds own 96.98% of the company.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Several other equities research analysts have also commented on RLAY. UBS Group set a $26.00 price objective on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Barclays lifted their target price on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their price target on Relay Therapeutics from $28.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday. Guggenheim restated a "buy" rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Finally, JonesTrading upgraded Relay Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Relay Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $25.83.

Relay Therapeutics Stock Performance

NASDAQ:RLAY opened at $19.86 on Friday. Relay Therapeutics has a fifty-two week low of $3.31 and a fifty-two week high of $20.79. The firm has a market cap of $4.35 billion, a PE ratio of -12.65 and a beta of 1.69. The business has a 50 day moving average price of $18.24 and a 200-day moving average price of $13.92.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. Research analysts predict that Relay Therapeutics will post -1.58 EPS for the current year.

Insider Activity

In related news, CEO Sanjiv Patel sold 48,199 shares of the company's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total transaction of $943,736.42. Following the completion of the sale, the chief executive officer directly owned 615,898 shares in the company, valued at $12,059,282.84. This represents a 7.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Thomas Catinazzo sold 187,163 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the sale, the chief financial officer owned 177,461 shares of the company's stock, valued at approximately $3,011,513.17. This trade represents a 51.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 409,639 shares of company stock valued at $7,233,399. 5.04% of the stock is currently owned by company insiders.

Institutional Trading of Relay Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Torren Management LLC purchased a new position in Relay Therapeutics in the fourth quarter valued at $30,000. KBC Group NV purchased a new stake in shares of Relay Therapeutics during the 1st quarter worth about $34,000. Allworth Financial LP acquired a new stake in shares of Relay Therapeutics during the 2nd quarter valued at about $34,000. Smartleaf Asset Management LLC grew its position in shares of Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company's stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Relay Therapeutics in the 4th quarter valued at about $46,000. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source